This hypothesis is supported by recent genome-wide association studies (GWAS) linking specific polymorphisms in inflammation-associated genes such as complement receptor-1 (CR1) [26], CD33 [13, 31] or triggering receptor expressed on myeloid cells-2 (TREM2) [8] to an increased risk for AD. The gene discussed is CD33; the disease is Alzheimer disease.